Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Trial Profile

A multicenter, randomized, addition to baseline treatment, double-blind, placebo-controlled, phase 3 study to evaluate the efficacy and safety of Satralizumab (SA237) in patients with Neuromyelitis Optica (NMO) and NMO Spectrum Disorder (NMOSD)

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Satralizumab (Primary)
  • Indications Neuromyelitis optica
  • Focus Registrational; Therapeutic Use
  • Acronyms SAkuraSky
  • Sponsors Chugai Pharmaceutical; Roche
  • Most Recent Events

    • 08 Nov 2019 According to an Chugai Pharmaceutical media release, the company announced that it filed a new drug application(NDA) to the Ministry of Health, Labour and Welfare (MHLW) for satralizumab for the treatment of neuromyelitis optica spectrum disorder (NMOSD). The application is based on the phase III trials SakuraStar and SAkuraSky and will be reviewed under priority review in Japan.
    • 30 Oct 2019 According to a Chugai Pharmaceutical media release, European Medicines Agency (EMA) accepted the Marketing Authorisation Application and the US FDA accepted the Biologics License Application (BLA) for satralizumab in adult and adolescent patients with neuromyelitis optica spectrum disorder. EMA granting it Accelerated Assessment. The CHMP recommendation and the FDA decision are expected in 2020. The applications are based on the phase III trial SakuraStar study and SAkuraSky study.
    • 13 Sep 2019 According to a Chugai Pharmaceutical media release, based on the data from SakuraStar Study and SAkuraSky Study, the Ministry of Health, Labour and Welfare (MHLW) has granted Orphan Drug Designation for Satralizumab in Neuromyelitis Optica and Neuromyelitis Optica Spectrum Disorder.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top